Summary:
Northern California Research is conducting a study for a new medication to treat diabetes. The main purpose of the study is to compare the effectiveness of albiglutide (liquid) in comparison to the already FDA approved medication, albiglutide lyophilized (freeze-dried powder). Albiglutide (liquid) is a subcutaneous injection; it will be administered once a week in the abdomen, thigh, or upper arm. For the first 4 weeks you will receive 30 mg of albiglutide and will then be up-titrated to 50 mg albiglutide for the remaining 22 weeks of the study. You will have weekly visits throughout the length of the study. The study is 8 months long and there will be 29 office visits.
Qualified Participants Must:
• Be Between 18 and 80 years of age
•
Be in general good health
•
Be taking Metformin only for diabetes
•
Have sugars that are still too high (A1C 7.0-10.0)
Qualified Participants May Receive:
All study related visits, tests, and study medication will be provided to the participant at no cost. Compensation for time and travel may also be provided.